{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:40:03Z","timestamp":1750844403891,"version":"3.41.0"},"reference-count":5,"publisher":"Oxford University Press (OUP)","issue":"7","license":[{"start":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T00:00:00Z","timestamp":1736985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,25]]},"abstract":"<jats:title>Teaser Text<\/jats:title>\n               <jats:p>This article reviews the findings of Wu et al. regarding the risk of malignancy in patients with psoriasis who were treated with long-term tumour necrosis factor-\u03b1 inhibitors. While the study found no significant increase in the risk of most cancers, it highlighted a higher risk of nonmelanoma skin cancers, particularly squamous cell carcinoma, in patients with psoriatic arthritis. The article discusses the clinical implications for patients with psoriasis who have a history of malignancy, advocating for a personalized treatment approach, vigilant monitoring and the need for further research to better understand the relationship between biologic therapy and cancer recurrence.<\/jats:p>","DOI":"10.1093\/ced\/llaf031","type":"journal-article","created":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T08:03:03Z","timestamp":1737014583000},"page":"1426-1427","source":"Crossref","is-referenced-by-count":0,"title":["Comment on \u2018The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-\u03b1 inhibitor: a systematic review and meta-analysis\u2019: risk of cancer recurrence with biologics in psoriasis"],"prefix":"10.1093","volume":"50","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5166-8738","authenticated-orcid":false,"given":"Aparna","family":"Potluru","sequence":"first","affiliation":[{"name":"Department of Dermatology, Leicester Royal Infirmary , NHS East Midlands ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0796-7233","authenticated-orcid":false,"given":"Yasmin","family":"Nikookam","sequence":"additional","affiliation":[{"name":"Guy\u2019s and St Thomas\u2019 Hospital NHS Trust ,","place":["UK"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,1,16]]},"reference":[{"key":"2025062505021823600_llaf031-B1","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1093\/ced\/llae503","article-title":"The risk of malignancy in patients with psoriasis treated with long-term tumour necrosis factor-alpha inhibitors: a\u202fsystematic review and meta-analysis","volume":"50","author":"Wu","year":"2025","journal-title":"Clin Exp Dermatol"},{"key":"2025062505021823600_llaf031-B2","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1080\/09546634.2021.1970706","article-title":"Biologic treatment for psoriasis in cancer patients: should they still be considered forbidden?","volume":"33","author":"Mastorino","year":"2021","journal-title":"J Dermatolog Treat"},{"key":"2025062505021823600_llaf031-B3","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1080\/14712598.2022.2152322","article-title":"Biologic treatment of \u00adpsoriasis in oncologic patients","volume":"22","author":"Rusi\u00f1ol","year":"2022","journal-title":"Expert Opin Biol Ther"},{"key":"2025062505021823600_llaf031-B4","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.jaad.2016.11.041","article-title":"Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"Suppl","key":"2025062505021823600_llaf031-B5","doi-asserted-by":"crossref","first-page":"AB61","DOI":"10.1016\/j.jaad.2024.07.252","article-title":"Malignancy rates in patients with a history of malignancy in the Psoriasis Longitudinal Assessment and Registry (PSOLAR)","volume":"91","author":"Langley","year":"2024","journal-title":"J Am Acad Dermatol"}],"container-title":["Clinical and Experimental Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ced\/advance-article-pdf\/doi\/10.1093\/ced\/llaf031\/61456487\/llaf031.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1426\/61456487\/llaf031.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ced\/article-pdf\/50\/7\/1426\/61456487\/llaf031.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,25]],"date-time":"2025-06-25T09:02:26Z","timestamp":1750842146000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ced\/article\/50\/7\/1426\/7958169"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,16]]},"references-count":5,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2025,1,16]]},"published-print":{"date-parts":[[2025,6,25]]}},"URL":"https:\/\/doi.org\/10.1093\/ced\/llaf031","relation":{},"ISSN":["0307-6938","1365-2230"],"issn-type":[{"type":"print","value":"0307-6938"},{"type":"electronic","value":"1365-2230"}],"subject":[],"published-other":{"date-parts":[[2025,7]]},"published":{"date-parts":[[2025,1,16]]}}}